Arizona State Retirement System lowered its stake in shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) by 1.4% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 289,111 shares of the company’s stock after selling 4,089 shares during the period. Arizona State Retirement System’s holdings in Endo International were worth $4,866,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its position in shares of Endo International by 13.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,446,852 shares of the company’s stock valued at $23,074,000 after purchasing an additional 284,599 shares during the last quarter. New York State Teachers Retirement System increased its position in shares of Endo International by 27.0% during the 2nd quarter. New York State Teachers Retirement System now owns 356,957 shares of the company’s stock valued at $3,366,000 after purchasing an additional 75,844 shares during the last quarter. Diamond Hill Capital Management Inc. increased its position in shares of Endo International by 1.0% during the 2nd quarter. Diamond Hill Capital Management Inc. now owns 1,100,259 shares of the company’s stock valued at $10,375,000 after purchasing an additional 10,600 shares during the last quarter. Sivik Global Healthcare LLC purchased a new stake in shares of Endo International during the 2nd quarter valued at about $1,697,000. Finally, Schroder Investment Management Group increased its position in shares of Endo International by 78.1% during the 2nd quarter. Schroder Investment Management Group now owns 747,571 shares of the company’s stock valued at $7,349,000 after purchasing an additional 327,775 shares during the last quarter. Institutional investors and hedge funds own 98.43% of the company’s stock.
ENDP has been the subject of several research reports. Royal Bank of Canada raised shares of Endo International from a “sector perform” rating to an “outperform” rating and set a $26.00 price target for the company in a research report on Monday, August 13th. Zacks Investment Research raised shares of Endo International from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Monday, September 24th. Goldman Sachs Group raised shares of Endo International from a “sell” rating to a “neutral” rating and upped their price target for the company from $14.00 to $15.00 in a research report on Tuesday, September 11th. TheStreet raised shares of Endo International from a “d” rating to a “c-” rating in a research report on Monday, August 20th. Finally, BidaskClub lowered shares of Endo International from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 8th. Fifteen equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $14.91.
In related news, Director Roger H. Kimmel sold 26,074 shares of the stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total value of $414,576.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.80% of the company’s stock.
Endo International stock opened at $17.14 on Wednesday. The company has a market capitalization of $3.85 billion, a P/E ratio of 4.46, a PEG ratio of 1.65 and a beta of 0.65. Endo International PLC has a 12-month low of $5.27 and a 12-month high of $18.50.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Wednesday, August 8th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.54 by $0.22. The company had revenue of $714.70 million during the quarter, compared to analyst estimates of $679.72 million. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The firm’s quarterly revenue was down 18.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.93 EPS. As a group, analysts predict that Endo International PLC will post 2.6 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://theenterpriseleader.com/2018/11/07/endo-international-plc-endp-shares-sold-by-arizona-state-retirement-system.html.
Endo International Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Want to see what other hedge funds are holding ENDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endo International PLC (NASDAQ:ENDP) (TSE:ENL).
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.